Latest stories on TENX
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight
Investing.com Analyst Ratings61 · neutralanalyst
Tenax Therapeutics, Inc. (TENX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow
Seeking Alpha55 · neutralgeneral
Tenax Therapeutics Updates Phase 3 LEVEL Trial Strategy
TipRanks56 · neutralproduct/pr
TENAX THERAPEUTICS, INC. (TENX) files 8-K
SEC 8-K50 · neutralgeneral
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
StockTitan56 · neutralgeneral
Guggenheim downgrades Tenax Therapeutics on clinical, regulatory uncertainty
The Fly32 · bearishanalyst
Tenax Therapeutics downgraded to Neutral from Buy at Guggenheim
The Fly48 · neutralanalyst
Why is Tenax Therapeutics stock volatile today?
Investing.com Markets50 · neutralgeneral
Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103
The Fly59 · neutralproduct/pr
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss
Seeking Alpha48 · neutralproduct/pr
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
StockTitan63 · neutralproduct/pr
Tenax rises on over $1.8M insider buying
Seeking Alpha63 · neutralgeneral
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
PR Newswire19 · bearishgeneral
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Criteo (CRTO)
GlobeNewswire32 · bearishgeneral
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX)
GlobeNewswire28 · bearishgeneral
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
Barchart50 · neutralgeneral
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics
PR Newswire22 · bearishgeneral
Tenax Therapeutics Downgraded To Neutral From Buy At Chardan
The Fly52 · neutralanalyst
Legal Scrutiny Intensifies on TENX After Phase 3 Trial Failure—What Are the Key Concerns for Investors?
August 11, 2026
MarketChameleon28 · bearishgeneral
Guggenheim cuts Tenax Therapeutics price target to $4 on trial miss
Investing.com Analyst Ratings28 · bearishanalyst
Tenax Therapeutics Price Target Lowered To 4 From 35 At Canaccord
The Fly22 · bearishanalyst
Tenax Therapeutics price target lowered to $4 from $40 at Guggenheim
The Fly22 · bearishanalyst
Tenax Therapeutics Price Target Lowered To 4 From 26 At Leerink
The Fly22 · bearishanalyst